Abstract. The pharmacokinetics of total and free prednisolone (PSL) in six healthy men, with or without pretreatment with oral glycyrrhizin (GL), was investigated to confirm whether oral administration of GL influences the metabolism of PSL in man. Each subject received an intravenous administration of 0.096 mg/kg of prednisolone hemisuccinate (PSL-HS) with or without pretreatment with 50 mg of oral GL four times. Blood samples were taken from a peripheral vein at 5, 10, 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 h after the start of PSL-HS infusion. The concentrations of total PSL in plasma were analyzed by high-performance liquid chromatography, and the free PSL was measured by an isocolloidosmolar equilibrium dialysis method. The pharmacokinetic parameters of PSL were determined by non-compartment analysis. Oral administration of GL was found to significantly increase the concentrations of total PSL at 6, 8 h, and of free PSL at 4, 6 and 8 h after PSL-HS infusion. Moreover, oral administration of GL was also found to modify the pharmacokinetics of both total and free PSL. After oral administration of GL, the area under the curve (AUC) was significantly increased, the total plasma clearance (CL) was significantly decreased, and the mean residence time (MRT) was significantly prolonged. However, the volume of distribution (Vdss) showed no evident change. This suggests that oral administration of GL increases the plasma PSL concentrations and influences its pharmacokinetics by inhibiting its metabolism, but not by affecting its distribution.
important to clarify whether oral administration of GL also increases the plasma concentration of PSL or influences the pharmacokinetics of PSL in humans. For this purpose, in this present work, we measured the plasma concentrations of total and free PSL and investigated the pharmacokinetics of PSL in six healthy men after intravenous infusion of a low dose of prednisolone-hemisuccinate (PSL-HS), with or without an oral dose of GL. Materials and Methods
Subjects
Six male subjects with an average age of 24.0 (range 20-33) years and with average weight of 58.2 (range 48-70) kg were included in this study. All subjects had the content of the experiments and the possible side-effects of PSL explained to 
Equilibrium dialysis for free PSL
The free PSL percentages (F-P%) in plasma samples were detected by the isocolloidosmolar equilibrium dialysis method [8] described previously [1] . In summary, each sample (0.5 ml of plasma) in a visking tube was dialyzed against a 3% dextran Krebs Ringer solution, containing 10 nCi/ml of [2, 4, 6, 7-3H] prednisolone with specific activity of 1.68 TBq/mmol (Amersham). After 6 h of dialysis, the radioactivities in the outer dialysate and inner plasma were counted by scintillator. The F-P% and free PSL concentration (F-P concentration) were calculated by means of the formula of Matsui et al. 
Results
Plasma concentrations of total PSL Figure 2 shows the plasma concentration vs. time of total PSL. Plasma PSL was detected by HPLC until 8 to 10 h after PSL-HS infusion. The mean total PSL concentrations increased to the peak during the first 15 min after PSL-HS infusion and decreased in a two-phase slope. The mean total PSL concentrations were higher in the GLpretreated group than in the control group. A significant difference was found at 6 and 8 h after PSL-HS infusion.
Free PSL in plasma expressed as a percentage Figure 3 shows the free PSL expressed as a percentage vs. time. The mean free PSL percentages in GL-pretreated group were higher than those in the control group. A significant difference was found at 3, 4, 6 and 8 h after PSL-HS infusion.
Plasma concentrations of free PSL Figure 4 shows the plasma concentration vs. time for free PSL. The mean free PSL concentrations in the GL-pretreated group were higher than those in the control group. A significant difference was found at 4, 6 and 8 h after PSL-HS infusion.
AUC (Area Under the Curve) Figure 5 shows the AUCs of total and free PSL in each subject. After pretreatment with oral GL, the AUCs of both total and free PSL were Vdss (Volume of distribution in steady state) Figure 8 shows the Vdss of total and free PSL in each subject. No significant difference was found between the Vdss of total and free PSL for the GL-pretreated group and the control group (Table 1) .
Discussion
We previously reported that an intravenous administration of GL results in an increase in the plasma concentrations of PSL and influences the pharmacokinetics of PSL in healthy men [1] . Ojima et al. [7] also reported that an intravenous administration of GL prolonged the half-life of PSL in patients during long-term treatment with PSL. However, the effect of oral GL on the pharmacokinetics of PSL in humans is still unknown. In this study, the oral administration of GL was found to significantly increase the concentration of total PSL at 6, 8 h, and the concentra- action of oral GL on the effects of PSL is stronger than that of intravenous GL is still unknown, because the subjects in these two experiments were different. Statistical analysis of the pharmacokinetic parameters of PSL in these two studies was performed by unpaired Student's t-test and no significant difference was found. The dosage and administration regimen still need to be elucidated. The plasma concentrations of GL and GA were also determined by HPLC and enzyme immunoassay [19, 20] . Only GA but not GL was detected (data not shown) . The concentrations of GA reached a peak between 45 min and 1.5 h after the last adminsitration of GL. This agrees with the results of our previous studies showing that GL itself cannot be detected in plasma when it is orally administered [3, 4] . It seems that GL has been metabolized to GA before it appears in the peripheral blood. The place where oral GL is metabolized to GA is still unknown. Hattori et al.
[ 21] , reported that GL was found to be metabolized to GA by human intestinal flora. In one of our other experiments [22] , the concentrations of GL and GA in the peripheral venous blood, abdominal aortic blood, and portal venous blood were measured after rats were given an oral dose of GL. Only GA but not GL was detected in all blood samples. This suggests that oral GL is metabolized to GA in the intestines, but not in the liver. It is still unknown whether GL can be metabolized by liver enzymes when the oral dose of GL is over the metabolic ability of intestinal flora. Thus, the main active component of GL when given orally is GA. but not GL. In clinics, Ojima et al. [6] reported that the ora. administration of GL potentiated the effects of PSL in some patients with rheumatoid arthritis or polyarteritis nodosa. This fact taken together witlour results suggests that the oral adminsitration of GL can potentiate the effects of PSL by increasing its plasma concentration through the inhibition of its metabolism. The effects of the combinatior treatment with PSL and GL are worthy of further evaluation.
